Jacqueline T. Lenmark, Esq. KELLER, REYNOLDS, DRAKE, JOHNSON & GILLESPIE, P.C. 50 South Last Chance Gulch, Suite 4 P.O. Box 598 Helena, MT 59624 Telephone: (406) 442-0230 Facsimile: (406) 449-2256

Email: jtlenmark@kellerlawmt.com

Attorney for Applicants

## BEFORE THE COMMISSIONER OF SECURITIES AND INSURANCE OFFICE OF THE STATE AUDITOR STATE OF MONTANA

IN THE MATTER OF THE CONVERSION OF BLUE CROSS AND BLUE SHIELD OF MONTANA, INC. AND ALLIANCE WITH HEALTH CARE SERVICE CORPORATION,	) ) ) )	Case No.:	INS-2012-238
Applicants.	) ) )		

#### **DIRECT TESTIMONY OF**

CALVIN E. SWARTLEY, CFA, ASA MOSS ADAMS LLP

ON BEHALF OF APPLICANTS

BLUE CROSS BLUE SHIELD OF MONTANA AND HEALTH CARE SERVICE CORPORATION, A MUTUAL LEGAL RESERVE COMPANY

**FEBRUARY 8, 2013** 

1	Q.	PLEASE STATE YOUR NAME, POSITION AND BUSINESS ADDRESS.
2	A.	My name is Calvin Swartley. I am a Senior Manager of Moss Adams LLP and a member
3		of its Valuation & Litigation Services Group. My business address is 805 SW Broadway
4		Suite 1200, Portland, Oregon, 97205.
5	Q.	HOW LONG HAVE YOU BEEN WITH MOSS ADAMS LLP?
6	A.	Since 1998.
7	Q.	PLEASE DESCRIBE YOUR EDUCATIONAL BACKGROUND,
8		QUALIFICATIONS AND EXPERIENCE.
9	A.	I graduated in 1993 from Lewis & Clark College in Portland, Oregon with a Bachelor of
10		Science in Business Administration. I received a Master of Business Administration
11		degree from Washington University in St. Louis, Missouri in 1998. In 2001, I received a
12		Chartered Financial Analyst (CFA) designation from the CFA Institute. In 2003, I
13		became an Accredited Senior Appraiser (ASA) from the American Society of Appraisers.
14		I am in good standing as a member of the CFA Institute, the American Society of
15		Appraisers, the Portland Chapter of the ASA and the CFA Society of Portland.
16	Q.	HAVE YOU PREVIOUSLY TESTIFIED IN FORMAL PROCEEDINGS BEFORE
17		AN OFFICER OF THIS STATE OR IN FORMAL PROCEEDINGS IN ANY
18		OTHER STATE OR THE FEDERAL GOVERNMENT?
19	A.	No, I have not.
20	Q.	ARE YOU FAMILIAR WITH THE TRANSACTION THAT IS THE SUBJECT
21		OF THE PROCEEDING?

1	A.	Yes, I am.
2	Q.	WHAT IS YOUR INVOLVEMENT IN THE TRANSACTION THAT IS THE
3		SUBJECT OF THE PROCEEDING?
4	A.	I was retained by Blue Cross Blue Shield of Montana ("BCBSMT" or "Company") in
5		August, 2012 to determine the fair market value of its total surplus. As part of that
6		analysis, I determined the fair market value of the total equity of the Company's
7		subsidiary, Health-E-Web, and the fair market value of certain of the Company's assets
8		and liabilities for financial planning purposes as of June 30, 2012. I was also retained to
9		assist BCBSMT in related responses to any regulatory or other proceedings or inquiries
10		regarding our valuation.
11	Q.	HAD YOU OR YOUR FIRM BEEN RETAINED BY BCBSMT OR HEALTH
12		CARE SERVICE CORPORATION TO PERFORM ANY OTHER SERVICES
13		PRIOR TO YOUR ENGAGEMENT FOR THAT VALUATION?
14	A.	No.
15	Q.	DID YOU PERFORM THE VALUATION ANALYSES THAT YOU WERE
16		RETAINED BY BCBSMT TO PERFORM?
17	A.	Yes, I did. I prepared a Report which was provided to BCBSMT on November 12, 2012
18		regarding Valuation Analysis Blue Cross Blue Shield of Montana as of June 30, 2012,
19		which is attached to my testimony as Exhibit 1 (the "Valuation Analysis.").
20	Q.	WERE YOU INVOLVED IN THE NEGOTIATIONS OF THE PROPOSED
21		TRANSACTION BETWEEN HCSC AND BCBSMT?
22	Α.	No, I was not.

	Υ.
2 A. I will testify on behalf of the applicants in this proceeding, BCBSMT and	d Health Care
3 Service Corporation, a Mutual Legal Reserve Company ("HCSC"), regar	rding our
4 calculation of the fair market value of the total surplus of BCBSMT. I w	rill also testify as
to facts relating to Moss Adams' engagement by BCBSMT.	
6 Q. DID YOU PERFORM A FAIR MARKET VALUATION OF THE T	TOTAL
7 SURPLUS OF BCBSMT?	
8 A. Yes, I did.	
9 Q. WHAT VALUE DID YOU PLACE ON THE TOTAL SURPLUS OF	F BCBSMT?
10 A. I valued the surplus at \$166.2 million.	
11 Q. HOW DID YOU ARRIVE AT THAT VALUE?	
12 A. I began the valuation by considering the factors identified in Internal Rev	venue Service
Ruling 59-60 for determining fair market value, which is the price at which	ch property
would change hands between a willing buyer and seller.	
15 I then considered three valuation approaches: (1) the Income Approach, i	in which
estimated future returns are discounted to present value at an appropriate	rate of return on
investment; (2) the Market Approach, in which valuation ratios derived fi	rom market
transactions involving companies that are similar to the subject business (	(past
transactions involving the subject business, if any, are also considered); a	and (3) the
Asset-Based Approach, in which the assets and liabilities of the business	are restated
from historical cost to fair market value.	

1		Within the Market Approach, I considered both a public company analysis and a merger		
2		and acquisition analysis. The public company analysis uses stock market transactions		
3		involving publicly traded companies that are similar in nature to the subject business,		
4		while the merger and acquisition analysis uses merger and acquisition transactions		
5		involving companies that are similar in nature to the subject business.		
6		Within the Asset-Based Approach, I considered both the direct Asset-Based Approach		
7		and the Residual Income Approach. In the direct Asset-Based Approach, the Company's		
8		net asset value is estimated by restating the value of assets and liabilities from historical		
9		cost to estimated fair market value. The Residual Income Approach utilizes the results of		
10		the Asset-Based Approach and includes the present value of the Company's expected		
11		future residual income.		
12		I valued BCBSMT surplus under each approach and arriv	red at the following indicated	
13		surplus values by approach:		
14		Income Approach	\$125,406,000	
15		Market Approach (Public Company Analysis)	\$175,651,000	
16		Market Approach (Merger and Acquisition Analysis)	\$147,247,000	
17		Residual Income Approach	\$164,168,000	
18		Direct Asset-Based Approach	\$146,557,000	
19	Q.	HOW DID YOU REACH A FINAL VALUE NUMBE	R UTILIZING THAT	
20		RANGE OF VALUES?		
21	A.	The final step in our valuation process was to review each	of the approaches above and	

reconcile them to arrive at a final estimated surplus value. The weight given to each

22

approach depends on the quantity and quality of available data, the valuation function and purpose, the value premise and definition and the reliability of the analysis. I assigned some weight (5%) to the Income Approach because it represents the amount a prudent investor would pay for expected future cash flows based on market rates of returns and the Company's specific risks. The Market Approach (Public Company Analysis) was given significant weight (35%) because it reflects current stock market pricing for reasonably comparable businesses that represent alternative investment opportunities. I also gave significant weight (60%) to the Residual Income Approach within the Asset-Based Approach because it captures the value of the company's total surplus as well as future earnings ability in excess of a potential investor's return on equity. I assigned no weight (0%) to the Market Approach (Merger and Acquisition Analysis) because of limits in finding recent transactions for closely similar companies and difficulties using merger and acquisition data. I also assigned no weight to the direct Asset-Based Approach because of significant overlap between that approach and the Residual Income Approach. I believe the Residual Income Approach better captures the Company's future excess earnings ability in addition to the book value of surplus. Applying these weighting factors against the indicated surplus values determined under the Income Approach, Residual Income Approach and Market Approach (Public Company Analysis), I arrived at the estimate of \$166,200,000 as the fair market value of the company's total surplus on a majority interest, going forward basis. Q. WHAT DATA AND OTHER INFORMATION DID YOU RELY ON IN ARRIVING AT YOUR VALUATION?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

1	A.	I relied primarily on BCBSMT's detailed historical financial statements and financial
2		projections provided by BCBSMT. I also discussed with BCBSMT senior management
3		the current and future operations of BCBSMT, and reviewed information concerning the
4		industry and economy in which BCBSMT operates, including a search for comparable
5		public companies and merger and acquisition data of comparable companies. I also
6		conducted a site visit to BCBSMT in September, 2012.
7		I also relied on the November 9, 2012, report prepared by Actuarial Services & Financial
8		Modeling, Inc. ("ActMod"), an actuarial and financial modeling company with
9		specialized expertise in actuarial services related to the health care industry, which was
10		incorporated into the Residual Income Approach of my report. I relied on ActMod's
11		actuarial appraisal of the \$17.6 million present value of BCBSMT's expected future
12		residual income as of June 30, 2012.
13	Q.	DID YOU REVIEW THE ACTMOD VALUATION BEFORE YOU RELIED ON
14		IT?
15	<b>A.</b>	Yes, I did. I reviewed the underlying assumptions and methodology.
16	Q.	WHY DID YOU RELY ON ANOTHER VALUATION EXPERT'S WORK IN
17		YOUR REPORT?
18	A.	It is my understanding that ActMod is a very specialized actuarial valuation organization,
19		with significant experience in the health insurance industry. BCBSMT advised me when
20		I was retained that ActMod was retained to do an actuarial valuation focused on the core
21		insurance business of BCBSMT rather than undertake a more comprehensive financial

valuation of BCBSMT's entire business. I was comfortable with that because of

ActMod's actuarial expertise in the health insurance business.

A.

# Q. DID YOU PERFORM A VALUATION OF THE ASSETS AND LIABILITIES OF BCBSMT?

A. With the exception of the valuation I did of BCBSMT and the subsidiary, Health-E Web, and various real estate owned by BCBSMT, I did not perform individual market value estimates of each asset and liability recorded by BCBSMT. I utilized information from BCBSMT management to adjust any recorded assets and liabilities to fair market values, as needed, for purposes of incorporating those restated values into the direct Asset-Based Approach analysis (Exhibit 22) and Residual Income approach (Exhibit 21).

# Q. WHAT INFORMATION DID YOU RELY ON IN ARRIVING AT THE RESTATED ASSET AND LIABILITY VALUES?

My analysis included a review of various financial statements and analysis, including historical income statements and balance sheets, management projections of financial statements, an internal analysis of various real estate holdings, actuarial studies, life insurance statements, bank and other financial institution statements, the sale proceeds of various assets, etc. A listing of the information used in our analysis can be found in Schedule 3: Sources of Information in our report. Any adjustments to historical cost were made based on discussions with management. The restated asset and liability values I arrived at under this methodology are reported in Exhibit 22 of our report, which is a summary of my conclusions under the direct Asset-Based Approach, and also in Exhibit 24, which is a more detailed management report I prepared showing potential

1 transactional allocation of asset, liability and estimated residual income values underlying 2 our estimate of surplus value under the Residual Income Approach (see Exhibit 21). 3 Q. WHAT WAS THE PURPOSE OF EXHIBIT 24? 4 A. Exhibit 24 is a more detailed, line-item restatement of the balance sheet using the 5 estimates I arrived at under the Residual Income Approach (see Exhibit 22). BCBSMT 6 management requested this balance sheet to assist it in analyzing business transactions 7 potentially involving the transfer of assets and/or liabilities to another entity or purchaser. 8 It has no direct relevance to the valuation, but reflects the facts used in the valuation. 9 Q HOW DID YOU ARRIVE AT THE VALUES AND ALLOCATIONS IN EXHIBIT 10 24? 11 A. I identified by line item the restated historical cost of BCBSMT's assets and liabilities 12 performed under the direct Asset Based Approach (Exhibit 22) and, as required under the 13 Residual Income Approach, added the \$17.6M present value of residual income reflected 14 in Exhibit 21 of our report to arrive at an "Adjusted Assets Less Liabilities" (or surplus 15 value) of \$164,168,000. I then assigned assets and liabilities to one of two columns, 16 "Destination NewCo" or "Destination OldCo", based on discussions and analysis 17 provided by management of BCBSMT. With the exceptions of the addition to the balance

### 20 Q. WHAT INFORMATION DID YOU RELY ON IN ARRIVING AT THESE

same as the values assigned in Exhibit 22 to each asset and liability.

sheet of the estimated \$17.6M present value of the Residual Income, the values were the

21 VALUES?

18

19

1 Adjustments to historical cost were made based on a review of various financial 2 statements and analysis, including historical income statements and balance sheets, 3 management prepared information, an internal analysis of various real estate holdings, 4 actuarial studies, life insurance statements, bank and other financial institution 5 statements, the sale proceeds of various assets, etc. and other indications of value 6 specific to certain assets and liabilities, as reported (Exhibit I, Exhibits 21, 22, and 24). 7 Allocations of assets and liabilities between "Destination NewCo" and "Destination OldCo" were made based on discussions and analysis provided by management of 8 9 Q. DID YOU CONSIDER CAPITAL EXPENDITURES IN YOUR VALUATION? 10 Yes, I did. A. 11 Q. WHAT AMOUNT OF CAPITAL INVESTMENT DID YOU INCLUDE IN YOUR 12 VALUATION AND WHY? 13 A. Based on information provided by BCBSMT management, I learned that BCBSMT's 14 recent financial and operating challenges had prevented it from implementing even 15 baseline capital improvements needed with respect to its administrative and claims 16 processing systems. I also learned that ACA demands would require additional capital 17 expenditures above and beyond recurring investments. Based on that information, I 18 included in my valuation at Exhibit 12 recurring capital expenditures, exclusive of non-19 recurring upgrades, of approximately \$48.8M. Based on management estimates of 20 approximately \$60M of proposed investments, we projected \$20.8M additional capital 21 expenditures on a present value basis for the period 2013-2032, as shown in my report at 22 Exhibit 13.

1	Ų.	WHEN WAS YOUR FINAL REPORT DELIVERED TO BUSSIII!
2	A.	November 12, 2012.
3	Q:	DID HCSC HAVE ANY INPUT INTO YOUR VALUATION OPINION BEFORE
4		YOU DELIVERED THE REPORT TO BCBSMT?
5	A.	No.
6	Q:	DID EITHER BCBSMT OR HCSC INFLUENCE YOU OR ATTEMPT TO
7		INFLUENCE YOUR OPINION IN ANY WAY?
8	A.	I had no conversations or communications with HCSC during the preparation of my
9		report or the formation of my opinions, which have not changed since my report was
10		delivered to BCBSMT on 11/12/2012. As I previously stated, BCBSMT management
11		provided me with historical information and discussed critical assumptions. BCBSMT
12		did not attempt to and did not influence my opinions.
13	Q:	HOW WERE YOU COMPENSATED FOR YOUR REPORT?
14	A.	I was compensated at my hourly rates for professional services provided. My
15		compensation was not contingent upon any of my findings or opinions.
16	Q.	DOES THIS CONCLUDE YOUR TESTIMONY?
17	A.	Yes.

#### **VERIFICATION**

STATE OF Oregon	)
	) ss
COUNTY OF Multhomah	)

I, Calvin E. Swartley, being first duly sworn, upon my oath, state that I have read, know and understand the contents of the foregoing testimony and that the statements contained therein are true and correct to the best of my knowledge, information and belief.

CALVÍN E. SWARTLEY

SUBSCRIBED, SWORN TO AND ACKNOWLEDGED before me this day of February, 2013, by Calvin E. Sunrtley.

My Commission Expires:

10-12-2015

OFFICIAL SEAL
JENNIFER N. BURNETT
NOTARY PUBLIC-OREGON
COMMISSION NO. 462661
MY COMMISSION EXPIRES OCTOBER 12, 2015

Respectfully submitted this 8 day of Libruary, 2013.

KELLER, REYNOLDS, DRAKE, JOHNSON & GILLESPIE, P.C.

Jacqueline T. Lenmark, Esq. 50 South Last Chance Gulch

P.O. Box 598

Helena, Montana 59624

#### CERTIFICATE OF SERVICE

I, Jacqueline T. Lenmark, KELLER, REYNOLDS, DRAKE, JOHNSON & GILLESPIE, P.C., certify that on 2013, I served a true and correct copy of the foregoing Direct Testimony of Calvin E. Swartley, CFA, ASA, by mailing it first class postage prepaid to:

Ms. Sybil Shults
Office of the Commissioner of
Securities & Insurance
State Auditor's Office
840 Helena Avenue
Helena MT 59601

Honorable W. William Leaphart 1772 University Avenue Helena, MT 59601

Jesse Laslovich, Esq.
Nick Mazanec, Esq.
Office of the Commissioner of
Securities & Insurance
State Auditor's Office
840 Helena Avenue
Helena, MT 59601

Kelley Hubbard, Esq. Michael Black, Esq. Montana Department of Justice 215 North Sanders, Third Floor P.O. Box 201401 Helena, MT 59620-1401

DATED this 8 day of Libruary, 2013.

Jacqueline T. Lenmark